Q2 2026 saw 9% constant currency revenue growth to $125.8M, with On-X and stent grafts leading gains. Adjusted EBITDA rose to $26.4M, and FY26 guidance was reiterated for both revenue and EBITDA. Key milestones included FDA approvals, the Endospan acquisition, and strong clinical data.Original docu…
Q2 2026 saw 9% constant currency revenue growth to $125.8M, with On-X and stent grafts leading gains. Adjusted EBITDA rose to $26.4M, and FY26 guidance was reiterated for both revenue and EBITDA. Key milestones included FDA approvals, the Endospan acquisition, and strong clinical data.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
